The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational study

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Zhang, Jie ^a   Delzell, Elizabeth ^a   Xie, Fenglong ^b   Baddley, John W ^c   Spettell, Claire ^d   Mcmahan, Raechele M ^e   Fernandes, Joaquim ^d   Chen, Lang ^b   Winthrop, Kevin ^f   Curtis, Jeffrey R ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d AETNA   (United States)

^e Aetna Specialty Pharmacy   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE; AUTACOID;

ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENTERITIS; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROPORTIONAL HAZARDS MODEL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; VACCINATION; AGED; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AUTOIMMUNE DISEASES; COHORT STUDIES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80054810870     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3497     Document Type: Article

References (23)

1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin 2008, 26:675-697. viii, 10.1016/j.ncl.2008.03.011, 2754837, 18657721.
2. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009, 109:S13-17.
3. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349. 10.4065/82.11.1341, 17976353.
4. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005, 20:748-753. 10.1111/j.1525-1497.2005.0150.x, 1490195, 16050886.
5. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005, 133:245-253. 10.1017/S095026880400281X, 2870243, 15816149.
6. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004, 4:108-115. 10.1046/j.1600-6143.2003.00287.x, 14678041.
7. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57:1431-1438. 10.1002/art.23112, 18050184.
8. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744. 10.1001/jama.2009.146, 19224750.
9. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, Carmona L. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010, 69:1751-1755. 10.1136/ard.2009.125658, 20551153.
10. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30; quiz CE32-34.
11. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784. 10.1002/art.23721, 18512708.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619. 10.1016/0895-4356(92)90133-8, 1607900.
13. Breslow NE, Day NE. Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency data. J Chronic Dis 1975, 28:289-303. 10.1016/0021-9681(75)90010-7, 1141424.
14. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010, 51:197-213. 10.1086/653605, 20550454.
15. Whitley RJ, Gnann JW. Herpes zoster in the age of focused immunosuppressive therapy. JAMA 2009, 301:774-775. 10.1001/jama.2009.150, 19224757.
16. Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009, 28:653-655. 10.1097/INF.0b013e3181998f06, 2868313, 19561431.
17. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008, 121:e150-156. 10.1542/peds.2007-0564, 18086820.
18. Son M, Shapiro ED, LaRussa P, Neu N, Michalik DE, Meglin M, Jurgrau A, Bitar W, Vasquez M, Flynn P, Gershon AA. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 2010, 201:1806-1810. 10.1086/652798, 2871955, 20441519.
19. Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L, Oliveira AC, Lima RA. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken) 2010, 62:896-898.
20. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. 10.1056/NEJMoa051016, 15930418.
21. Schmader K, George LK, Burchett BM, Hamilton JD, Pieper CF. Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc 1998, 46:973-977.
22. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, Dong F, Beaty BL, Tan L, Babbel C, Dickinson LM, Kempe A. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010, 152:555-560.
23. High K. Immunizations in older adults. Clin Geriatr Med 2007, 23:669-685. viii-ix, 10.1016/j.cger.2007.03.007, 17631240.